Last reviewed · How we verify
Liposome-encapsulated Daunorubicin-Cytarabine
Liposome-encapsulated Daunorubicin-Cytarabine is a Liposomal chemotherapy combination Small molecule drug developed by Fred Hutchinson Cancer Center. It is currently in Phase 3 development for Acute myeloid leukemia (AML) in elderly or unfit patients, Relapsed or refractory acute leukemia. Also known as: CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal Cytarabine (AraC)-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin.
A liposome-encapsulated combination of two chemotherapy drugs (daunorubicin and cytarabine) that delivers cytotoxic agents directly into leukemic cells to inhibit DNA synthesis and induce cell death.
A liposome-encapsulated combination of two chemotherapy drugs (daunorubicin and cytarabine) that delivers cytotoxic agents directly into leukemic cells to inhibit DNA synthesis and induce cell death. Used for Acute myeloid leukemia (AML) in elderly or unfit patients, Relapsed or refractory acute leukemia.
At a glance
| Generic name | Liposome-encapsulated Daunorubicin-Cytarabine |
|---|---|
| Also known as | CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal Cytarabine (AraC)-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine |
| Sponsor | Fred Hutchinson Cancer Center |
| Drug class | Liposomal chemotherapy combination |
| Target | DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Daunorubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation, while cytarabine is a nucleoside analog that inhibits DNA polymerase and gets incorporated into DNA, causing chain termination. Encapsulation in liposomes enhances cellular uptake and reduces systemic toxicity by preferentially targeting leukemic blasts.
Approved indications
- Acute myeloid leukemia (AML) in elderly or unfit patients
- Relapsed or refractory acute leukemia
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Infection
- Mucositis
- Nausea and vomiting
- Cardiotoxicity
- Hepatotoxicity
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Tazemetostat and Palbociclib With CPX-351for R/R AML (PHASE1)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (PHASE2)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
- CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposome-encapsulated Daunorubicin-Cytarabine CI brief — competitive landscape report
- Liposome-encapsulated Daunorubicin-Cytarabine updates RSS · CI watch RSS
- Fred Hutchinson Cancer Center portfolio CI
Frequently asked questions about Liposome-encapsulated Daunorubicin-Cytarabine
What is Liposome-encapsulated Daunorubicin-Cytarabine?
How does Liposome-encapsulated Daunorubicin-Cytarabine work?
What is Liposome-encapsulated Daunorubicin-Cytarabine used for?
Who makes Liposome-encapsulated Daunorubicin-Cytarabine?
Is Liposome-encapsulated Daunorubicin-Cytarabine also known as anything else?
What drug class is Liposome-encapsulated Daunorubicin-Cytarabine in?
What development phase is Liposome-encapsulated Daunorubicin-Cytarabine in?
What are the side effects of Liposome-encapsulated Daunorubicin-Cytarabine?
What does Liposome-encapsulated Daunorubicin-Cytarabine target?
Related
- Drug class: All Liposomal chemotherapy combination drugs
- Target: All drugs targeting DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine)
- Manufacturer: Fred Hutchinson Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML) in elderly or unfit patients
- Indication: Drugs for Relapsed or refractory acute leukemia
- Also known as: CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal Cytarabine (AraC)-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine
- Compare: Liposome-encapsulated Daunorubicin-Cytarabine vs similar drugs
- Pricing: Liposome-encapsulated Daunorubicin-Cytarabine cost, discount & access